Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).
This study has been completed.
Study NCT00435825   Information provided by Hoffmann-La Roche

First Received on February 15, 2007.   Last Updated on September 18, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis B, Chronic
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
peginterferon alfa-2a [Pegasys]
Additional drug interventions recognized in this trial
Interferon-alpha
Peginterferon alfa-2a
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Hoffmann-La Roche


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services